Does sorafenib increase mortality in the setting of myocardial infarction?
Sorafenib exacerbates cardiac damage and dramatically increases mortality post-myocardial infarction by inducing myocyte necrosis and impairing endogenous stem cell-mediated repair.
Sorafenib cardiotoxicity results from myocyte necrosis rather than from any direct effect on myocyte function. Surviving myocytes undergo pathological hypertrophy. Inhibition of c-kit+ stem cell proliferation by inducing apoptosis exacerbates damage by decreasing endogenous cardiac repair. In the setting of MI, which also causes large-scale cell loss, sorafenib cardiotoxicity dramatically increases mortality.
Duran et al. (Thu,) studied this question.